Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE plus umbilical cord blood CIK cells versus TACE alone in primary hepatocellular carcinoma
ChiCTR-ONRC-12002936Phase 2Completed
- Sponsor
- 901st Hospital of the People's Liberation Army
- Start
- Apr 2012
- Modality
- Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of umbilical cord blood cytokine-induced killer cells in hepatocellular carcinoma (HCC) (2 arms), sponsored by 901st Hospital of the People's Liberation Army. Primary endpoints: Disease control rate and Progression-free survival. Started Apr 2012; status: completed.
02
Drugs
umbilical cord blood cytokine-induced killer cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-ONRC-12002936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-12002936.